BRS3-3-8 - Eicosanoid / SPM Balance
(Shifting from Pro-Inflammatory to Calming Pro-Resolving Lipid Signals)
1. Mission & Overview + Dietary Levers
Mission
Shift lipid mediator balance from pro-inflammatory eicosanoids toward pro-resolving signals that terminate inflammation.
Short-term n-3 fatty acid supplementation raised some circulating pro-resolving mediators in healthy adults. Not every mediator rose, and this is not a disease-resolution outcome.
Intervention Dominance: Diet-Dominant — Dietary Requirements
Not every specialised pro-resolving mediator rose. Aspirin added no further rise. This is not a disease-resolution outcome. The rise is in healthy adults and does not include every mediator.
- EPA
- DHA
EPA and DHA are already the dietary requirements above. They are not repeated here.
No mapping established.
Overview
Resolvins and protectins are made from EPA and DHA, and they help inflammation finish rather than only blocking it. Serhan and Petasis (2011) describe that pathway. [1] Barden et al. (2014) found that 2.4 g a day of n-3 fatty acids for five days raised RvE1 and several pathway markers in healthy adults. [9] Not every mediator rose.
- Benefits: These mediators support the finishing of inflammation, which is a different job from blocking the signal at the start. [1]
- Implementation Notes: EPA and DHA are the substrates. [1] The intake that raised some mediators was 2.4 g a day for five days in healthy adults, not a disease-resolution dose. [9]
- Biological Relevance: Cytokine intensity is a later messenger readout — see PM7.
2. Primary Biological Effects
↑ pro-resolving mediator bias; ↓ pro-inflammatory eicosanoid dominance
3. Intervention Levers
No evidence-qualified System Optimisation Practice is established.
No lifestyle lever is established. Sleep, stress, and activity were not shown to change these mediators.
4. Mechanistic Basis
Summary
Inflammation termination depends on lipid mediators that actively resolve rather than merely suppress immune activity. EPA and DHA substrate availability shapes whether signalling bias moves toward specialized pro-resolving mediators within BRS3(FM3) - Inflammation Resolution Capacity.
(Lipid mediator balance)
Serhan and Petasis (2011) describe resolvins and protectins as mediators made from EPA and DHA, distinct from blockade of inflammation. [1]
(Fatty-acid substrate competition)
Barden et al. (2014) found that five days of n-3 fatty acids raised some of those mediators in healthy adults, and not others. [9] An evolutionary omega-6 to omega-3 review is not that measurement.
(Boundaries of the mechanism)
Downstream cytokine-network readouts are handled by BRS3-FM3-PM7 - Cytokine Network Modulation. Membrane PUFA protection upstream belongs to BRS3-FM2-PM5 - Lipid Peroxidation Control. Transcriptional inflammatory control is represented by BRS3-FM1-PM1 - NF-kB Signalling Regulation.
(Integration within BRS3)
This PM anchors resolution-oriented lipid signalling within BRS3(FM3), supported by habitual EPA/DHA intake through §4.1.1 Direct and/or Derived Dietary Requirements.
4.1 Scientific Findings (2)
Scientific Findings and their source assessments are available in Evidence & Audit.
5. BRS Pathways and Connections
5.1 BRS Pathways
- None listed
5.2 Cross-BRS Mechanism Relationships
Primary Mechanisms in other Biological Regulatory Systems that directly interact with, constrain or support this mechanism.
- BRS1-FM3-PM7 — Neuronal Membrane DHA Incorporation — membrane long-chain PUFA substrate pools feeding specialized pro-resolving mediator formation
- BRS5-FM1-PM2 — LPS / Endotoxin Containment — gut endotoxin containment upstream of systemic cytokine network tone
- BRS5(FM1) — Gut Barrier Integrity and Immune Interface — gut–immune interface context influencing inflammatory resolution substrate availability
- BRS6(FM1) — Glycaemic–Insulin Stability & Cognitive Energy Availability — post-prandial glycaemic context conditioning inflammatory cytokine expression
5.3 Local BRS Mechanism Relationships
Related Primary Mechanisms within the same Biological Regulatory System that collectively support the integrated biological function.
- BRS3-FM3-PM7 — Cytokine Network Modulation — downstream cytokine readouts of resolution-oriented lipid signalling
- BRS3-FM2-PM5 — Lipid Peroxidation Control — upstream membrane PUFA integrity preserving SPM substrate quality
7. Phenome Connections
These mappings are translational relationships, not single-mechanism outcome claims. Phenomes are emergent functional patterns supported by multiple interacting PMs across the BRAIN Framework.
Each Phenome relationship has two independent ratings. They are not combined or averaged.
Biology → Phenome Relationship Strength
How direct and important is this biological mechanism expected to be to the Phenome within the BRAIN model?
Evidence Confidence
How strongly does the adjudicated evidence support this particular biology → Phenome relationship?
- Biology → Phenome Relationship Strength: Low–Medium
- Evidence Confidence: Low–Medium
- Rationale: Specialized pro-resolving mediators actively terminate inflammation without suppressing immune surveillance — supporting cognitive clarity context through resolution-oriented lipid signalling.
- Biology → Phenome Relationship Strength: Low–Medium
- Evidence Confidence: Low–Medium
- Rationale: Omega-3-derived resolution biology may modulate affective inflammatory context when EPA/DHA substrate and omega-6:omega-3 balance are adequate over habitual intake.
- Biology → Phenome Relationship Strength: Low
- Evidence Confidence: Low
- Rationale: Resolution-phase lipid mediator balance may intersect attention-relevant inflammatory tone; direct ADHD SPM outcome evidence remains limited.
- Biology → Phenome Relationship Strength: Medium
- Evidence Confidence: Medium
- Rationale: Persistent inflammatory signalling and impaired resolution-phase lipid mediator balance are recognised contributors to anxious perseverative cognition within neuroimmune framing (Slavich & Irwin, 2014; Marsland et al., 2017). SPM-oriented resolution biology and human omega-3 intervention reduced inflammatory markers and anxiety symptoms alongside cytokine remodelling (Kiecolt-Glaser et al., 2011; Ferguson et al., 2014). This PM governs eicosanoid–SPM balance — not omega-3 treatment — and attached anxiety outcomes require one inferential step to PH016 rather than direct perseverative-thought measurement.
- Biology → Phenome Relationship Strength: Low
- Evidence Confidence: Low–Medium
- Rationale: Resolution-phase eicosanoid balance may modulate inflammatory tone intersecting reward-processing and depressive biology in translational framing; Gruber et al. (2023) reviews insulin–dopamine reward disruption in depression as adjacent context.
8. References
- [1] Serhan and Petasis (2011) — Resolvins and Protectins in Inflammation Resolution
- [2] Simopoulos (2011) — Omega-6/Omega-3 Ratio and the Brain
- [3] Ferguson et al. (2014) — Omega‐3 PUFA Supplementation and the Response to Evoked Endotoxemia in Healthy Volunteers
- [4] Camuesco et al. (2006) — Intestinal Anti-Inflammatory Activity of Quercitrin
- [5] Kiecolt-Glaser et al. (2011) — A Randomized Controlled Trial
- [6] Slavich & Irwin (2014) — From Stress to Inflammation and Major Depressive Disorder
- [7] Marsland et al. (2017) — Systemic Inflammation and Resting State Connectivity of the Default Mode Network
- [8] Gruber et al. (2023) — Impact of Insulin and Insulin Resistance on Brain Dopamine Signalling and Reward
- [9] Barden et al. (2014) — Short-term n-3 fatty acids and proresolving mediators
No validated structured conversion route is currently projected for this PM. This does not remove or reclassify its existing dietary inputs.
Mapping state: admitted-food-targets-resolved.